奥沙利铂联合改良吉西他滨治疗晚期胆系肿瘤临床疗效及安全性观察

Clinical Efficacy and Safety of Oxaliplatin Combined with Modified Gemcitabine in the Treatment of Advanced Biliary Tumors

目的探究奥沙利铂联合改良吉西他滨治疗晚期胆系肿瘤临床疗效及安全性。方法选取90例晚期胆系肿瘤患者作为研究对象,随机分为对照组和观察组,每组各45例。对照组采用常规方案进行治疗,观察组采用改良方案进行治疗,对比两组患者的临床疗效、不良反应及血清炎性因子情况。结果观察组患者的临床疗效明显优于对照组,观察组患者的不良反应发生率明显低于对照组,各项对比结果数据差异显著,均具有统计学意义(P <0. 05),研究表明两组患者IL-6比较无统计学差异,观察组的IL-2、TNF-α及PGE2水平均优于对照组。结论采用奥沙利铂联合改良吉西他滨治疗晚期胆系肿瘤临床疗效显著,安全性有所提高,值得推广。

Objective To explore the clinical efficacy and safety of oxaliplatin combined with modified gemcitabine in the treatment of advanced biliary tract tumors. Methods 90 patients with advanced biliary tumor who were treated in our hospital from June 2015 to July 2018 were selected as the subjects of this study. They were randomly divided into the control group and the observation group,45 cases in each group. The control group were treated with routine regimen and the observation group were treated with improved regimen. The clinical efficacy and adverse reactions of the two groups were compared. Results The clinical efficacy of the observation group was significantly better than that of the control group,and the incidence of adverse reactions in the observation group was significantly lower than that of the control group. There was significant difference in the comparison results( P < 0. 05). Conclusion Oxaliplatin combined with modified gemcitabine in the treatment of advanced biliary tumor has significant clinical efficacy,safety has been improved,it is worth promoting.